UBS Group’s Psyence Biomedical PBM Stock Holding History
Bought
Maintained
Sold
Other funds holding PBM
UBS Group's PBM Position: Q3 2026 in Review
UBS Group increased its Psyence Biomedical (PBM) stake by 450% in Q3 2026, buying an estimated $1.1K and bringing the position to 330 shares worth $1.8K. The position accounts for ﹤0.01% of the portfolio, ranked #10164.
UBS Group first reported a position in PBM in Q1 2024 and has held it in 9 quarters since. The position peaked at $26.8K in Q4 2024. 10 funds tracked by Wall St. Rank hold PBM as of Q3 2026.
- UBS Group held 330 shares of Psyence Biomedical worth $1.8K as of Q3 2026.
- UBS Group bought 270 Psyence Biomedical shares in Q3 2026, an estimated $1.1K.
- Psyence Biomedical made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #10164 holding.
- UBS Group first reported a position in Psyence Biomedical in Q1 2024 and has held it in 9 quarters since.
- UBS Group's Psyence Biomedical position peaked at $26.8K in Q4 2024.
- 10 funds tracked by Wall St. Rank held Psyence Biomedical as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.